Abstract
Objective: to examine the effect of angiotensin converting enzyme inhibition (ACEI) on soluble intercellular adhesion molecule 1 (sICAM-1) and C-reactive protein (CRP) in patients requiring coronary artery bypass grafting (CABG).Method: subgroup analysis of 42 patients randomised to Quinapril (40 mg daily determined) and 45 to placebo. sICAM-1 and CRP were ≥4 weeks before and 1 year after surgery.Results: there was no difference in sICAM-1 at baseline (142.2 μg/L vs 136.6 μg/L). There was significant reduction in s-ICAM-1 in patients receiving quinapril (142.2±10.8 μg/L vs 125.6±9.4 μg/L, p<0.05) but not placebo (136.6±10.2 μg/L vs 131.2±11.7 μg/L, p=NS). Levels of C-reactive protein remained unchanged in both groups (3.70±0.85 vs 2.73±0.32 mg/L, 2.85±0.48 vs 3.16±0.50 mg/L).Conclusions: ACEI reduces sICAM-1 in patients undergoing CABG. The benefits of ACEI may partly be due to a reduction of the vascular inflammatory response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Vascular and Endovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
